Natalizumab throughout pregnancy: Risk of low platelet count in the newborn at delivery

Rev Neurol (Paris). 2016 Feb;172(2):165-6. doi: 10.1016/j.neurol.2015.07.007. Epub 2015 Aug 28.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Delivery, Obstetric
  • Female
  • Humans
  • Infant, Newborn / blood
  • Infant, Newborn, Diseases / blood
  • Infant, Newborn, Diseases / chemically induced*
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Natalizumab / therapeutic use*
  • Platelet Count
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Prenatal Exposure Delayed Effects / blood*
  • Prenatal Exposure Delayed Effects / chemically induced
  • Risk Factors
  • Thrombocytopenia / blood
  • Thrombocytopenia / chemically induced*
  • Thrombocytopenia / congenital

Substances

  • Natalizumab